Velmanase alfa

Brand names: Lamzede · Active ingredient: Velmanase Alfa-Tycv

In short: LAMZEDE is indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.

Forms & strengthsFor injection: 10 mg of velmanase alfa-tycv as a white to off-white lyophilized powder with a cake-like appearance in a single-dose vial for reconstitution.
LabelChiesi USA, Inc.
Label updatedMar 01, 2023

What is Velmanase alfa used for?

LAMZEDE is indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.

âš  Boxed warning (FDA's strongest warning)

Hypersensitivity Reactions Including Anaphylaxis

Patients treated with LAMZEDE have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including

cardiopulmonary resuscitation equipment

, should be readily available during LAMZEDE administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs,

discontinue

LAMZEDE immediately and

initiate

appropriate medical treatment. In patients with severe hypersensitivity reaction, a desensitization procedure to LAMZEDE may be considered

.

Velmanase alfa dosage

For females of reproductive potential, verify that the patient is not pregnant

.

Prior to LAMZEDE administration, consider pre-treating with antihistamines, antipyretics, and/or corticosteroids .

The recommended dosage of LAMZEDE is 1 mg/kg (actual body weight) administered once every week as an intravenous infusion.

The total volume of infusion is determined by the patient’s actual body weight and should be administered over a minimum of 60 minutes for patients weighing up to 49 kg. Patients weighing 50 kg and greater should be infused at a maximum infusion rate of 25 mL/hour to control the protein load [

s

ee

Dosage and Administration (

2.4

)].

If one or more doses are missed, restart the treatment as soon as possible, as long as it is at least 3 days from the next scheduled dose. If it is within 3 days from the next scheduled dose, give only the next dose per schedule.

In the event of a severe hypersensitivity reaction (including anaphylaxis) or severe infusion-associated reaction (IAR), immediately discontinue LAMZEDE administration and initiate appropriate medical treatment. For additional recommendations in the event of a severe hypersensitivity reaction or IAR,

see Warnings and Precautions (

5.1

,

5.2

).

In the event of a mild to moderate hypersensitivity reaction or a mild to moderate IAR, consider temporarily holding the infusion for 15 to 30 minutes, slowing the infusion rate to 25% to 50% of the recommended rate, and initiating appropriate medical treatment .

If symptoms:

Persist despite temporarily holding or slowing the infusion, stop the infusion and monitor the patient. If symptoms continue to persist, discontinue the infusion, and consider re-initiating the infusion within 7 to 14 days at 25% to 50% of the recommended rate with appropriate pretreatment.

Subside following holding or slowing the infusion, resume infusion at 25% to 50% the recommended rate. If tolerated, increase the infusion rate by increments of 25% of the recommended rate until the recommended infusion rate is reached. Closely monitor the patient.

Use aseptic technique during preparation. Reconstitute LAMZEDE in the following manner:

Determine the number of LAMZEDE vials to be reconstituted based on the patient’s weight in kg and the recommended dose . Round the number of vials up to the next whole number.

Remove vials from the refrigerator and set aside for approximately 30 minutes to allow vials to come to room temperature.

Reconstitute each vial by slowly injecting 5 mL of Sterile Water for Injection, down the inside wall of each vial. Avoid adding the Sterile Water for Injection to the vial forcefully or directly onto the lyophilized powder to minimize foaming.

Allow the reconstituted vials to stand on the table for 5 – 15 minutes. …

How to take Velmanase alfa — instructions & advice from the label

H

ypersensitivity

R

eactions

Including Anaphylaxis and Infusion-Associated Reactions (IARs)

Advise the patient and caregiver that reactions related to the infusion may occur during and after LAMZEDE treatment, including anaphylactic reactions, other serious or severe hypersensitivity reactions, and IARs. Inform the patient and caregiver of the signs and symptoms of hypersensitivity reactions and IARs and to seek medical care should signs and symptoms occur .

Embryo-Fetal Toxicity

LAMZEDE may cause embryo-fetal harm. Advise the pregnant female of the potential risk to the fetus. Advise a female patient and caregiver to inform their healthcare provider of a known or suspected pregnancy [

see

Warnings and Precautions (

5.3

) and

Use in Specific Populations (

8.1

)

]

.

Advise a female of reproductive potential to use effective contraception during treatment and for 14 days after the last dose if LAMZEDE is discontinued .

Manufactured by:Chiesi Farmaceutici S.p.A. Via Palermo 26/A, 43122 Parma, Italy U.S. License No. 2245

Manufactured at:Patheon Italia S.p.A., Ferentino FR, Italy, 03013

Manufactured for:Chiesi USA, Inc., Cary NC, 27518, USA.Product of Germany. …

Warnings & precautions

Do not take this medicine if: None.

Hypersensitivity reactions including anaphylaxis have been reported in LAMZEDE-treated patients. In clinical trials, 19 (50%) LAMZEDE-treated patients (5 adult patients and 14 pediatric patients) experienced hypersensitivity reactions, including 2 (5%) patients (1 adult patient and 1 pediatric patient) who experienced anaphylaxis and an additional 3 (8%) pediatric patients who experienced severe hypersensitivity reactions that required medical treatment .

In the 5 patients who experienced anaphylaxis or severe hypersensitivity requiring medical treatment, 4 (80%) were anti-drug antibody (ADA) positive

.

Anaphylaxis and severe hypersensitivity signs and symptoms included cyanosis, hypotension, emesis, urticaria, erythema, facial swelling, pyrexia, and tremor.

Prior to LAMZEDE administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during LAMZEDE administration.

If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue LAMZEDE immediately and initiate appropriate medical treatment. Consider the risks and benefits of re-administering LAMZEDE following severe hypersensitivity reactions (including anaphylaxis). Patients may be rechallenged using slower infusion rates. In patients with severe hypersensitivity reaction, desensitization measures to LAMZEDE may be considered. If the decision is made to readminister LAMZEDE, ensure the patient tolerates the infusion. If the patient tolerates the infusion, the rate may be increased to reach the recommended dosage.

If a mild or moderate hypersensitivity reaction occurs, consider slowing the infusion rate or temporarily withholding the dose . …

Velmanase alfa side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Hypersensitivity Reactions Including Anaphylaxis

Infusion-Associated Reactions (IARs)

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse Reactions

F

rom

Trial

1

The safety of LAMZEDE was evaluated in Trial 1, which included a total of 15 LAMZEDE-treated patients (8 adult patients aged 18-35 years old and 7 pediatric patients aged 6-17 years old; 9 male, 6 female) with alpha-mannosidosis . All patients received LAMZEDE 1 mg/kg weekly via intravenous infusion for 52 weeks.

A serious adverse reaction of acute renal failure was reported in 1 (7%) LAMZEDE-treated patient .

Table 1 lists adverse reactions that occurred in at least 2 LAMZEDE-treated patients in Trial 1. …

About this medicine

Velmanase alfa-tycv, is lysosomal alpha-mannosidase produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cells. The amino acid sequence of the monomeric protein is identical to the naturally occurring human enzyme, alpha-mannosidase. Velmanase alfa-tycv has an approximate molecular weight of 130 kDa.

LAMZEDE (velmanase alfa-tycv) for injection is a sterile, preservative-free, white to off-white lyophilized powder with a cake-like appearance for intravenous infusion after reconstitution. Each single-dose vial contains 10 mg of velmanase alfa-tycv and the inactive ingredients dibasic sodium phosphate (2.47 mg), glycine (10.1 mg), mannitol (227.5 mg) and monobasic sodium phosphate (0.088 mg). After reconstitution with 5 mL Sterile Water for Injection, USP the resultant concentration is 2 mg/mL with pH of 7.5 ± 0.5.

How it works: Alpha-mannosidosis is a lysosomal storage disease that results from reduced activity of the enzyme alpha-mannosidase, caused by gene variants in Mannosidase Alpha Class 2B Member 1. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 36d50a08-60bd-40eb-807c-778d69bf2d2e. Read the full official label on DailyMed.